Structure-based insights illuminate key residues, conformational transitions, and binding pocket characteristics that dictate therapeutic agonist engagement

The glucagon-like peptide-1 receptor (GLP-1R) has emerged as a pivotal therapeutic target for type 2 diabetes and obesity, yet understanding how drugs engage this class B G protein-coupled receptor (GPCR) requires deciphering complex molecular choreography across multiple receptor domains. Recent structural biology advances, particularly through cryo-electron microscopy (cryo-EM) and molecular dynamics simulations, have revealed that GLP-1R activation involves a sophisticated interplay between peptide binding dynamics, conformational changes in transmembrane helices, and coordinated movements of extracellular domains. The receptor employs a two-domain binding mechanism where the extracellular domain (ECD) captures peptide C-termini as an affinity trap while the N-terminal peptide segments insert into the transmembrane domain (TMD) orthosteric pocket to trigger activation. This binding mode creates a deep, amphipathic pocket formed by residues from transmembrane helices 1, 2, 3, 5, 6, and 7, with critical contributions from Y152 (TM1), K197 (TM2), Q234 and Y241 (TM3), W306 and R310 (TM5), and E364 and H363 (TM6). Peptide N-terminal residues, particularly His1 and Glu9 in GLP-1, establish both hydrogen bonds and hydrophobic contacts with these binding pocket residues, with interaction persistence correlating directly with signaling efficacy. Molecular dynamics simulations have illuminated that different agonists exhibit distinct dynamics within this pocket, with native GLP-1 forming more stable interactions at the cavity base compared to oxyntomodulin or exendin-4. The extracellular loops play specialized roles: ECL2 stabilizes the peptide and couples binding to activation, ECL1 undergoes conformational rearrangements that differ between agonists, and ECL3 transitions from ECD-stabilizing interactions in the inactive state to facilitating TM7 rearrangements during activation. The hallmark of GLP-1R activation is the outward movement of TM6’s intracellular region by approximately 11.9 Å at residue R348, creating a cavity for Gs protein engagement. Notably, class B GPCRs like GLP-1R exhibit unique activation kinetics where Gs interaction can precede TM6 opening, contrasting with class A GPCRs, and once opened, TM6 relaxes back slowly, enabling sustained signaling. The ECD serves dual functions as both affinity trap and intrinsic agonist, with its conformational transition from a closed TMD-interacting state to an extended position being essential for activation, even when peptides are covalently linked to the receptor. Recent structural studies of therapeutically relevant agonists like tirzepatide have revealed that its weaker affinity for GLP-1R compared to GIPR stems from a bulkier N-terminal Tyr1 causing steric conflicts with W306, resulting in biased pharmacology with reduced receptor desensitization. Small molecule agonists bind to a more tightly packed orthosteric pocket with distinct ECL3 and TM7 positioning compared to peptides, yet converge on similar mechanisms to induce the critical TM6 conformational change. This structural understanding establishes that transient versus persistent interactions at the binding pocket base directly influence G protein activation kinetics, explaining how different agonists can produce biased signaling profiles despite targeting the same receptor, and provides a molecular framework for rational design of next-generation therapeutics with tailored pharmacological properties.